The Royal Court of Jersey sanctioned Shire’s proposed acquisition of Takeda Pharmaceuticals.
Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.
EnteraSense secured $4 million in funding for its gastrointestinal tract bleed-detecting capsule.
Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn’s disease treatment.
More articles on gastroenterology:
5 thoughts on Cologuard, gastroenterology’s future & the tax threatening Connecticut ASCs from Dr. Charles Adelmann
Landos’ IBD drug well-tolerated — 6 study insights
EnteraSense secures $4M in funding for bleed-detecting GI tract capsule — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
